SAN DIEGO, July 09, 2008 – Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that Dr. Susan M. Baxter, Executive Director of the California State University Program for Education and Research in Biotechnology (CSUPERB), has joined Histogen’s Board of Directors.
As Executive Director of CSUPERB, Dr. Baxter works with California State University (CSU) students, faculty and administrators system-wide to provide top-tier biotechnology education, capabilities and real-world research experience. CSUPERB serves as a liaison between the CSU and industry, academia, government, and the public in biotechnology matters.
“We are excited to welcome Dr. Susan Baxter to Histogen’s Board,” said Dr. Gail Naughton, CEO and Chairman of the Board for Histogen. “As someone with her finger on the pulse of the industry, Dr. Baxter will be an invaluable asset to Histogen as we grow the company and our presence in the regional biotechnology sector.”
Previously, Dr. Baxter served as Chief Operating Officer at the National Center for Genome Resources in Santa Fe, New Mexico, where she managed a portfolio of state- and federal-funded projects providing information technology for collaborative, interdisciplinary biotechnology research and education. Prior to this, Dr. Baxter served as Vice President of Research and Genome Analysis
for GeneFormatics, later Cengent Therapeutics, a drug discovery company in San Diego. In this position, she managed programs in both target and lead discovery.
“I think Histogen’s unique business model and rich product portfolio poise the Company to become a leader in the regenerative medicine field, and offer compelling opportunities for collaborations with other industry innovators” said Dr. Baxter. “I look forward to contributing to Histogen’s success, and continuing to develop the region’s life sciences community in this exciting, fast growing field.”
About Histogen Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. Through Histogen’s proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen’s human Extracellular Matrix (ECM) and HGEN-001, Histogen’s proprietary liquid formula. For more information, please visit http://www.histogeninc.com.
